ERBB2 and breast carcinoma: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors abemaciclib, palbociclib, and ribociclib, which are approved for the treatment of metastatic HR+/HER2 breast cancer, have also been examined in the adjuvant setting (Table 3).